Goldman Sachs lowered GE HealthCare rating from Buy to Neutral, citing macro pressures despite product momentum.
12‑month price target cut to $65 from $81, reflecting lower earnings estimates and a reduced valuation multiple.
EPS forecast for 2026 trimmed due to rising input costs; organic revenue growth seen at 3‑4% and EPS growth about 5%.
Patient care solutions lagged while imaging and diagnostics grew; China market weakness and local competition pose additional risks.